Associated Papers
Mutation profile and immunoscore signature in thymic carcinomas: An exploratory study and review of the literature.
Asselta R et al.
Thoracic Cancer, 2021
33704917 (PubMed )
Supplement: TCA-12-1271-s003.xls › Foglio1
Conventional chondrosarcoma with focal clear cell change: a clinicopathological and molecular analysis.
Lam SW et al.
Histopathology, 2019
Molecular Alterations in Thyroid Cancer: From Bench to Clinical Practice.
Tirrò E et al.
Genes, 2019
Prevalence of the single-nucleotide polymorphism rs11554137 (IDH1105GGT) in brain tumors of a cohort of Italian patients.
Acquaviva G et al.
Scientific Reports, 2018
Molecular mechanisms of isocitrate dehydrogenase 1 (IDH1) mutations identified in tumors: The role of size and hydrophobicity at residue 132 on catalytic efficiency.
Avellaneda Matteo D et al.
The Journal of Biological Chemistry, 2017
IDH1/2 mutations target a key hallmark of cancer by deregulating cellular metabolism in glioma.
Zhang C et al.
Neuro-oncology, 2013
Glioblastoma with oligodendroglial component represents a subgroup of glioblastoma with high prevalence of IDH1 mutation and association with younger age.
Ha SY et al.
Journal of Neuro-oncology, 2013
IDH1 and IDH2 mutations in tumorigenesis: mechanistic insights and clinical perspectives.
Yang H et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2012
Identification of additional IDH mutations associated with oncometabolite R(-)-2-hydroxyglutarate production.
Ward PS et al.
Oncogene, 2012
Identification of several novel non-p.R132 IDH1 variants in thyroid carcinomas.
Hemerly JP et al.
European Journal of Endocrinology, 2010
Select a paper to view details